- Home
- URGN vs FBIZ Comparison
URGN vs FBIZ Comparison
Compare URGN & FBIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- FBIZ
- Stock Information
- Founded
- URGN 2004
- FBIZ 1909
- Country
- URGN United States
- FBIZ United States
- Employees
- URGN N/A
- FBIZ N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- FBIZ Major Banks
- Sector
- URGN Health Care
- FBIZ Finance
- Exchange
- URGN Nasdaq
- FBIZ Nasdaq
- Market Cap
- URGN 465.9M
- FBIZ 450.2M
- IPO Year
- URGN 2017
- FBIZ N/A
- Fundamental
- Price
- URGN $11.06
- FBIZ $47.34
- Analyst Decision
- URGN Strong Buy
- FBIZ Strong Buy
- Analyst Count
- URGN 6
- FBIZ 4
- Target Price
- URGN $40.75
- FBIZ $58.75
- AVG Volume (30 Days)
- URGN 418.3K
- FBIZ 29.1K
- Earning Date
- URGN 03-10-2025
- FBIZ 04-24-2025
- Dividend Yield
- URGN N/A
- FBIZ 2.46%
- EPS Growth
- URGN N/A
- FBIZ 20.00
- EPS
- URGN N/A
- FBIZ 5.20
- Revenue
- URGN $90,398,000.00
- FBIZ $144,630,000.00
- Revenue This Year
- URGN $43.60
- FBIZ $17.65
- Revenue Next Year
- URGN $103.77
- FBIZ $9.14
- P/E Ratio
- URGN N/A
- FBIZ $9.06
- Revenue Growth
- URGN 9.29
- FBIZ 6.57
- 52 Week Low
- URGN $9.03
- FBIZ $32.56
- 52 Week High
- URGN $20.70
- FBIZ $56.46
- Technical
- Relative Strength Index (RSI)
- URGN 50.86
- FBIZ 40.51
- Support Level
- URGN $11.12
- FBIZ $47.49
- Resistance Level
- URGN $11.91
- FBIZ $50.10
- Average True Range (ATR)
- URGN 0.57
- FBIZ 1.27
- MACD
- URGN -0.02
- FBIZ 0.04
- Stochastic Oscillator
- URGN 26.40
- FBIZ 24.80
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in innovative solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About FBIZ First Business Financial Services Inc.
First Business Financial Services Inc operates as a bank holding company. The Bank operates as a business bank, focusing on delivering a full line of commercial banking products including commercial loans and commercial real estate loans, to meet the specific needs of small and medium-sized businesses, business owners, executives, professionals, and high-net-worth individuals. The company's products and services include commercial lending, SBA lending and servicing, asset-based lending, equipment financing, factoring, trust, and investment services, treasury management services, and a broad range of deposit products. Geographically all the business activity functioned through the region of the United States.